[go: up one dir, main page]

WO2016029267A1 - Procédé de culture de cellules souches mésenchymateuses - Google Patents

Procédé de culture de cellules souches mésenchymateuses Download PDF

Info

Publication number
WO2016029267A1
WO2016029267A1 PCT/AU2015/050498 AU2015050498W WO2016029267A1 WO 2016029267 A1 WO2016029267 A1 WO 2016029267A1 AU 2015050498 W AU2015050498 W AU 2015050498W WO 2016029267 A1 WO2016029267 A1 WO 2016029267A1
Authority
WO
WIPO (PCT)
Prior art keywords
mscs
cells
population
subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2015/050498
Other languages
English (en)
Inventor
Caroline GARGETT
Shanti GURUNG
Jerome Werkmeister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Prince Henrys Institute of Medical Research
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Prince Henrys Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903390A external-priority patent/AU2014903390A0/en
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO, Prince Henrys Institute of Medical Research filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of WO2016029267A1 publication Critical patent/WO2016029267A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)

Definitions

  • the present specification relates generally to a cell culture method for mesenchymal stem cells and other cells of related lineage.
  • Cell populations for use as cellular medicaments and in cell-based and tissue engineering therapies, in diagnostics and in screening protocols for therapeutic agents are also taught therein.
  • Stem cells are self-renewing, pluripotent or at least multipotent cells capable of proliferation and differentiation into various cell types (Eckfeldt et al. (2005) Nat. Rev. Mol. Cell Biol. 6(9) .726-737).
  • Embryonic stem cells derived from the inner mass of the blastocyst embryo, have long been thought of as having the most clinical benefit due to their pluripotency (Aivarez et al. (2012) J. Mol. Endocrinol 49(2):R&9- ⁇ 11).
  • adult stem cells have the potential to exhibit sufficient multipotency for use in cellular therapeutic protocols.
  • MSCs Mesenchymal stem (stromal) cells
  • stromal cells are multipotent, plastic adherent cells having a capacity to proliferate and exhibit clonogenic activity.
  • They have the capacity to differentiate into mesodermally-derived tissues such as bone, cartilage, muscle, stromal cells, tendon and connective tissue (Battula et al. (2009) Haematologica 94: 173-184; de la Garza-Rodea et al. (2011) Cell Transplant 20:271-231; Szpalski et al. (2012) Tissue Eng. Part B Rev. 75:258-269; Tuan et al. (2003) Arthritis Res. Ther. 5:32- 45; Xue et al. (2012) Biomaterials 33:5832-5840).
  • MSCs have conventionally been isolated from unfractionated bone marrow cells.
  • the isolation process has disadvantages by the unpredictable effects of co- cultured hematopoietic cells or other cells.
  • Improvements have been made using immunomagentic isolation and fluorescence-activated cell sorting (FACS) based on MSC- specific cell surface markers (or absence of markers) [Buhring et al. (2007) Ann. N.Y. Acad. Sci. 1106:262-271]. This includes selection for mesenchymal precursor cells (MPCs) using cell markers like STRO-1 and STRO-3 that can give rise to conventional MSCs (Gronthos et al. (2003) J. Cell Sci. 776: 1827-1835).
  • FACS immunomagentic isolation and fluorescence-activated cell sorting
  • endometrial MSCs or eMSCs
  • endometrial MSCs or eMSCs
  • eMSCs Gargett et al. (2009) Biol. Reprod. 80(6) A 136-W45; Chan et al. (2004) Biol. Reprod. 70 ⁇ : 1738-1750; Gargett et al. (2010) Mol. Hum. Reprod. 76(77, ) :818-834.
  • These cells can readily be obtained form uterine biopsy via the cervix without requiring an anesthetic or the level of invasiveness needed to obtain bone marrow or adipose MSCs.
  • MSCs appear to exert biological effects through secretion of soluble bioactive molecules, such as growth factors, angiogenic factors, cytokines and chemokines. These properties of MSCs have led to numerous clinical trials for a variety of diseases including graft versus host disease, cardio-vascular disease as a cell-based therapy or in tissue- engineered constructs where they may contribute to tissue repair and regeneration.
  • MSCs For the development of clinical protocols involving MSCs, these cells require expansion without differentiation, thus maintaining their multipotency.
  • a disadvantage of expanding MSCs in culture is their propensity to spontaneously differentiate into fibroblasts and other cell types. Whilst cell surface markers have been previously proposed, these tend not to distinguish between MSCs, fibroblasts or other differentiated forms (Rajaraman et al. (2013) Tissue Engineering 79(7 ⁇ :80-92).
  • sourcing of MSCs is largely limited to young healthy individuals; with age and disease, the relative abundance of MSCs is diminished which could limit the use of MSCs in autologous cell therapy.
  • the present disclosure teaches a protocol for expanding a sample comprising mammalian mesenchymal stem cells (MSCs) or precursor forms thereof such as mesenchymal precursor cells (MPCs) into a population comprising substantially non- differentiated, multipotent MSCs.
  • the expanded, multipotent MSC population has a range of clinical applications including in tissue regeneration, organ growth, repair and augmentation, tissue rejuvenation, cosmetic treatment and treatment of inflammatory and other diseases including graft versus host disease, host versus graft, cardiovascular disease, lung disease, liver disease, circulatory disorders and bone disease. Other conditions which can be treated include female subjects requiring pelvic organ prolapse repair or subjects in need of cartilage repair or who present with a hernia.
  • the expanded MSC population also has diagnostic applications and can be used in drug-screening assays.
  • the protocol enables a quality management system to reduce individual MSC variation. This in turn reduces the variability between patients treated and permits a more personalized medical approach to therapy.
  • the protocol comprises culturing a sample of cells comprising MSCs or their precursors (including mesenchymal precursor cells [MPCs]) in the presence of an agent which inhibits or otherwise antagonizes signaling by transforming growth factor- ⁇ (TGF ).
  • TGF transforming growth factor- ⁇
  • the culturing is conducted for a time and under conditions sufficient to expand the sample comprising MSCs into a population comprising multipotent cells.
  • the sample of cells is initially enriched for MSCs and/or MPCs.
  • the sample of cells comprising MSCs or MPCs can be derived from a range of tissue including endometrium, placenta, bone marrow, adipose tissue, menstrual blood and uterine or cervical biopsy. MSC samples can also be obtained from post-menopausal female subjects.
  • the MSC sample is from the endometrium such as in the form of biopsy tissue and comprises endometrial MSCs (eMSCs).
  • eMSCs endometrial MSCs
  • the MSC sample is from the placenta and comprises placental MSCs (pMSCs).
  • MSCs or eMSCs” or 'pMSCs” includes their precursor forms such as MPCs, eMPCs and pMPCs.
  • Cell surface markers useful for an initial enrichment of MSCs from a sample comprising MSCs include but are not limited to W5C5, CD29, CD44, CD49a, CD49e, CD90, CD73, CD105, CD106, CD140b, CD146, W3D5, W8B2, W1C5, W3C5, W4A5, W7C6 and a STRO marker such as STRO-1 or STRO-3.
  • the cell surface marker is W5C5, which recognises an epitope on the SUSD2 (Sushi domain containing 2) molecule.
  • cell enrichment it may be by any means including use of magnetic beads or other procedure involving immobilization of selected cells to a solid support via immunointeractive molecules (e.g. antibodies) followed by elution or the potential use of flow cytometry.
  • immunointeractive molecules e.g. antibodies
  • the sample comprising MSCs is cultured in the presence of an agent which inhibits or otherwise antagonizes TGF -mediated signaling.
  • the agent enables proliferation (i.e. expansion) while blocking or otherwise retarding differentiation and cellular senescence due to prolonged culturing.
  • the agent is generally a chemical compound, an antibody, a peptide or a nucleic acid molecule including a peptide or nucleic aptamer which inhibits activity of a component of the TGF signaling pathway or a gene encoding same.
  • Inhibition or antagonism of the TGF -mediated signaling pathway is proposed to reduce or prevent MSC differentiation without reducing expansion potential.
  • the agent inhibits signaling via transforming growth factor receptor- ⁇ (TGF -R).
  • TGF -R transforming growth factor receptor- ⁇
  • Any number of agents may be used to inhibit or otherwise antagonize TGF - or TGF -R mediated signaling including but not limited to 3-(6- methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l-carbothioamide, 4-[4-2,3- dihyrdo-l,4-benzodioxin-6-yl)-5-(2-pyridynl)-lH-imidazol-2-yl]-benzamide, 4-[4-[3-(2- pyridynl)-lH-pyrazol-4-yl]-2-pyridynl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide, 4-[3-(2- pyridynl)-lH-pyrazol-4-y
  • the agent is (3-(6-methylpyridin-2-yl)-N-phenyl-4- quinolin-4-ylpyrazole-l-carbothioamide) which is an activin receptor-like kinase inhibitor (ALK) and is also referred to as compound A83-01.
  • MSCs are, in an embodiment, eMSCs or pMSCs, including W5C5 + eMSCs and W5C5 + pMSCs.
  • eMSCs or pMSCs including W5C5 + eMSCs and W5C5 + pMSCs.
  • the MSCs are of human origin however, non-human MSCs such as equine MSCs are contemplated herein.
  • reference to MSCs, eMSCs and pMSCs include their precursor forms such as MPCs, eMPCs and pMPCs, respectively.
  • Contemplated herein is a method of cell therapy in a subject comprising the administration, locally or systemically, of an expanded population of multipotent MSCs generated by the culture method disclosed herein for a time and under conditions sufficient for the multipotent MSCs to differentiate into selected tissues.
  • autologous/homologous MSCs are used in the subject being treated.
  • Reference to "cell therapy” includes cell-based and tissue engineering therapies and cellular medicaments.
  • the present disclosure enables the expansion of MSCs to generate into a non- differentiated, multipotent cell population for use in a range of clinical applications, diagnostic assays and drug-screening protocols. It is in effect a quality management system to reduce cell variability and help facilitate a high likelihood of a successful and efficacious outcome. It is akin to a personalized medical protocol.
  • kits including a therapeutic kit is taught herein in compartment form comprising a culturing or washing medium, reconstituted in liquid form or not, and optionally a cellular support matrix upon which expanded MSCs can grow under culture conditions.
  • a TGF signaling inhibitor may optionally be included in a separate compartment.
  • SEQ ID NO Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO).
  • the SEQ ID NOs correspond numerically to the sequence identifiers ⁇ 400>1 (SEQ ID NO: l), ⁇ 400>2 (SEQ ID NO:2), etc.
  • a summary of the sequence identifiers is provided in Table 1.
  • a sequence listing is provided after the claims.
  • Figure 1 is a graphical representation of an analysis of eMSC phenotype markers.
  • Figure 2 is a graphical representation of autofluorescence of passage 6 eMSCs with or without A83-01 treatment. eMSCs were treated with or without A83-01 for 7 days at P6. Autofluorescence of the unstained eMSCs were determined by flowcytometry by normalizing the treated group. Data are mean ⁇ SEM. Autofluorescence is an indicator of senescent cells (old cells).
  • Figure 4 is a graphical representation of eMSC phenotype markers CD146, CD90, W5C5 and CD140b on passages 4 or 5 using flow cytometry.
  • the percentage of W5C5 + eMSCs is significantly increased with ⁇ ⁇ A83-01 treatment.
  • Cells were obtained from endometrial biopsies of three post menopausal women treated with Progynova for 2-3 weeks to thicken the endometrium.
  • the percentage range of W5C5 cells was large in untreated cells compared to treated cells (Table 4) indicating that the A83-01 treatment served as a significant quality management system to control the expanded cell population. Data are mean + SEM.
  • Figures 5A and B are a graphical representation showing dose response curve of A83-01 promotion of eMSC proliferation.
  • Figures 6A through D are graphical and photographic representations showing Phenotype of P6 eMSC cultured with or without A83-01 in serum free medium in 5% v/v 0 2 .
  • B Representative flow cytometric histograms of SUSD2+ eMSC treated with (black bar) and without (white bar) ⁇ ⁇ A83-01 and MFI summarized in (C).
  • Figures 7A through C are graphical and photographic representations showing functional MSC properties of P6 eMSC cultured with or without A83-01 in serum free medium.
  • A Representative culture plates seeded at clonal density (50 cell/cm 2 ).
  • B Graph shows Colony Forming Efficiency of P6 eMSC pre-treated with ⁇ ⁇ A83-01 or 0.01% v/v DMSO vehicle for 7 days in 5% v/v 0 2 in SFM followed by clonal culture at 50 cells/cm 2 in SFM for 4 weeks.
  • Figure 8 is a graphical representation showing, quantitative RT-PCR analysis of MSC genes.
  • ⁇ -Actin or GAPDH were used to normalize the mRNA level, and fold change was calculated using 2 " ⁇ € ⁇ .
  • FIGS 9A through F are graphical representations showing.
  • A83-01 blocks apoptosis and promotes eMSC proliferation.
  • FIG. 10 is a photographic representation of A83-01 pre-treated postmenopausal eMSC seeded on gelatin/polyamide mesh cultures in serum free medium.
  • Figure 11 is a graphical representation of eMSC phenotype markers CD146, CD90, W5C5 and CD 140b on placental MSC immuno-selected with W5C5 at passage 1 and cultured in serum free medium until passage 6. The cells were then grouped into untreated and treated A83-01. Data are based on flow cytometry and show the percentage positive cells expressing the individual markers. The percentage range of W5C5 + cells was large in untreated cells compared to treated cells (Table 5) indicating that the A83 -01 treatment served as a significant quality management system to control the expanded cell population. Data are mean + SEM.
  • the present disclosure relates to a culture method for expanding mesenchymal stem (stromal) cells (MSCs) into a population comprising substantially non-differentiated MSCs which retain multipotent capability.
  • MSCs mesenchymal stem cells
  • MSCs mesenchymal stem cells
  • MSCs mesenchymal stem cells
  • MSCs mesenchymal stem cells
  • eMSCs mesenchymal stem/stromal cells
  • All such cell types are encompassed herein by the term "mesenchymal stem cell” or "MSC”.
  • the MSCs are endometrial-derived MSCs (eMSCs).
  • pMSCs placental MSCs
  • MSCs include bone marrow, adipose tissue, menstrual blood and uterine or cervical biopsy.
  • Reference to MSCs, eMSCs and pMSCs includes their precursor forms such as MPCs, eMPCs and pMPCs.
  • MPCs eMPCs
  • pMPCs pMPCs
  • an MPC or eMPC or pMPC is taken to be encompassed by reference to MSC and eMSC and pMSC, respectively.
  • This disclosure provides a method for generating multipotent MSCs useful in therapeutic, diagnostic and drug discovery applications.
  • the disclosure teaches contacting a sample of cells comprising MSCs with a particular compound in order to inhibit or reduce TGF -mediated signaling which would otherwise lead to differentiation and/or cellular senescence due to prolonged culturing.
  • the sample of cells is first enriched for MSCs such as eMSCs or pMSCs.
  • MSCs such as eMSCs or pMSCs.
  • Reference to a "particular compound” includes a single agent and the use of multiple agents. Multiple agents may target various components within the TGF signaling pathway.
  • the instant disclosure teaches a protocol comprising obtaining a tissue or cell sample putatively comprising MSCs and dissociating the tissue or cell clumps by enzymatic and/or mechanical disruption such as using agitation, physical dissection, collagenase and/or deoxyribonuclease.
  • the resulting cell sample is regarded as a single cell suspension comprising single stromal cells and epithelial clumps.
  • the cells are then subject to filtration to remove epithelial clumps, then to centrifugal separation using a hydrophilic polysaccharide such as Ficol-Paque to remove blood cells and retain stromal cells and peripheral blood mononuclear cells.
  • immunointeractive molecules such as antibodies or other suitable ligands are used to enrich MSCs via selected cell surface markers prior to expansion.
  • Markers include but are not limited to any or all of W5C5, CD29, CD44, CD49a, CD49e, CD90, CD73, CD105, CD106, CD140b, CD146, W3D5, W8B2, W1C5, W3C5, W4A5, W7C6 and a STRO marker such as STRO-1 or STRO-3.
  • Some biomarkers may work more effectively when used in combination with other biomarkers.
  • antibodies to these markers are used either directly bound to a solid support such as magnetic beads or anti-immunoglobulin molecules bound to the solid support are used to capture specific antibody-labeled cells.
  • Cell isolation may also involve using flow cytometry.
  • the primary marker used to enrich cells is W5C5 which detects Sushi domain containing 2 (SUSD2).
  • the sample comprising MSCs is expanded without an initial enrichment step.
  • the result is a population comprising MSCs in a non- differentiated state having multipotent properties.
  • non-differentiated state includes MSCs in a substantially non-differentiated state.
  • the cell sample is not enriched for MSCs but is subject to direct MSC expansion conditions.
  • the MSCs are eMSCs or pMSCs which include eMPCs and pMPCs.
  • the next step is to expand the population comprising MSCs in a way which proliferates the MSCs while maintaining the cells in a substantially non-differentiated, multipotent state. This is accomplished by culturing the cells in the presence of an agent which is an inhibitor or antagonist of TGF - or TGF -receptor (TGF -R)-mediated signaling. It is proposed herein that MSCs can be expanded in the presence of the TGF or TGF -R signaling antagonist which will inhibit or retard differentiation into fibroblasts or other cell types and/or retard cellular senescence due to prolonged culturing. Generally, a serum free medium (SFM) is employed.
  • SFM serum free medium
  • Reference to the "serum free medium” or “SFM” include a medium comprising DMEM/F-12, 0.1-10% w/v antibiotic-antimyocotic, 0.5-10mM glutamine, 0.1-10% w/v lipid-rich bovine serum albumin (e.g. AlbuMAXI), 10-500 ⁇ g heparin, 50-500 ⁇ L- ascorbic acid, 10-200nM linoleic acid, 10-200 ⁇ , 2-mercapethanol and 0.1-5% v/v insulin-transferrin-slenium-sodium pyruvate (ITS-A).
  • ITS-A insulin-transferrin-slenium-sodium pyruvate
  • an aspect of the present disclosure is a method for proliferating a sample of cells comprising mammalian mesenchymal stem cells (MSCs) into a population of substantially non-differentiated, multipotent MSCs in an in vitro culture, the method comprising culturing the sample of cells in the presence of an agent which antagonizes TGF -mediated signaling for a time and under conditions sufficient to expand the sample comprising MSCs into a population of multipotent cells.
  • TGF -mediated includes signaling mediated by its receptor (TGF -R) or via TGF itself.
  • expanding includes "proliferating".
  • a method for expanding a sample of cells comprising mammalian mesenchymal stem cells (MSCs) into a population of substantially non-differentiated, multipotent MSCs in an in vitro culture comprising subjecting a sample of cells comprising MSCs to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched sample of cells in the presence of an agent which antagonizes TGF -mediated signaling pathway for a time and under conditions sufficient to expand the sample of MSCs into a population of multipotent cells.
  • MSCs mammalian mesenchymal stem cells
  • the agent targets TGFP-R.
  • a method for proliferating a sample comprising mammalian mesenchymal stem cells (MSCs) into a population of substantially non- differentiated, multipotent MSCs in an in vitro culture comprising culturing the sample of cells in the presence of an agent which antagonizes signaling via TGF -R for a time and under conditions sufficient to expand the sample comprising MSCs into a population of multipotent cells.
  • MSCs mammalian mesenchymal stem cells
  • a method for proliferating a sample comprising mammalian mesenchymal stem cells (MSCs) into a population of substantially non- differentiated, multipotent MSCs in an in vitro culture comprising subjecting a sample of cells comprising MSCs to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent which antagonizes signaling via the TGF -R for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells.
  • MSCs mammalian mesenchymal stem cells
  • inhibitor or “antagonist” or an agent which "antagonizes” in relation to TGF or TGF -R signaling is used interchangeably to refer to the agent which by inhibiting TGF /TGF -R mediated signaling, enables expansion and proliferation of MSCs without substantial differentiation into fibroblasts or other cell lineages and/or with reduced cellular senescence due to prolonged culturing.
  • an agent includes a single or multiple (e.g. 2 or more) agents.
  • An example of a suitable agent which antagonizes TGF or TGF -R signaling is a compound of Formula (I).
  • E is selected from:
  • G is N, O, CH or CZ 3 , wherein at least one G is N;
  • each Z 3 is independently a Ci-C 8 straight, branched, or cyclic hydrocarbon group, a
  • Ci-C 6 alkoxy group amide optionally substituted with Ci.C 6 straight or cyclic alkyl or C to C 6 straight or heterocyclicalkyl or, optionally, two Z groups, together with the carbon atoms to which the Z 3 groups are attached, combine to form a cyclic group;
  • Z 1 is H CO HAr, or CS HAr
  • N 0, 1, 2 or 3;
  • each Z 2 is independently a Ci-C 8 straight, branched or cyclic hydrocarbon group, a Ci-C 6 alkoxy group, or, optionally, two Z 2 groups, together with the carbon atoms to which said Z 2 groups are attached, combine to form a cyclic group.
  • the agent is a compound of Formula (II) having the structure:
  • Z 1 is H, CO HAr, or CS HAr
  • Ci-C 8 straight, branched, or cyclic hydrocarbon group
  • each n is independently, 0, 1, 2 or 3.
  • the agent is a compound of Formula (III) having the structure:
  • the compound, 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l- carbothioamide, is an activin receptor-like kinase inhibitor and is also referred to as A83- 01.
  • Reference to this or other TGF /TGF -R signaling inhibitors includes any and all pharmaceutically acceptable salts, solvates, tautomers and enantiomers.
  • various chemical derivatives and modified compounds including analogs, homologs, orthologs and paralogs are encompassed by reference to "an agent" in the present disclosure.
  • An example of a chemical derivative includes the compound of Formula (IV) which has the structure:
  • Z 1 is H, CO HAr or CS HAr
  • Z 2 is a C -C 8 straight, branched, or cyclic hydrocarbon group
  • each n is indpendently 0, 1, 2 or 3.
  • G is N, O, CH or CZ 3 , wherein at least one G is N;
  • each Z 3 is independently a Ci-C 8 straight, branched, or cyclic hydrocarbon group, a Ci-C 6 alkoxy group, amide optionally substituted with Ci-C 6 straight or cyclicalkyl or Ci- C 6 straight or heterocyclicalkyl or optionally, two Z 3 groups, together with the carbon atoms to which the Z 3 groups are attached, combine to form a cyclic group;
  • Z 1 is a Ci-C 8 straight, branched or cyclic hydrocarbon group, or an Ar group;
  • Z 2 is a Ci-C 8 straight, branched or cyclic hydrocarbon group, a Ci-C 6 alkoxy group, a -CO H 2 group, or a -CS H 2 group;
  • each n is independently 0, 1, 2 or 3.
  • Z 1 is Ci-C 8 straight, branched or cyclic hydrocarbon group, or an Ar group;
  • Z 2 is a Ci-C 8 straight, branched or cyclic hydrocarbon group, a Ci-C 6 alkoxy group,
  • Z 3 roups together form a -OCH 2 0- or -OCH 2 CH 2 0- group;
  • each n is independently 0, 1, 2 or 3.
  • Other compounds have the structure of Formula VIII:
  • G is N, CH or CZ 2 ,
  • Z 2 is a Ci-C 8 straight, branched or cyclic hydrocarbon group, a Ci-C 6 alkoxy group or amide optionally substituted with Ci-C 6 straight or cyclicalkyl or Ci-C 6 straight or heterocyclicalkyl;
  • Z 4 is a COZ 2 group, a CON(R 5 ) 2 group
  • each Z 5 is independently a hydrogen or C C 8 straight, branched or cyclic hydrocarbon group.
  • Z 2 is a Ci-C 8 straight, branched or cyclic hydrocarbon group, a Ci-C 6 alkoxy group or amide optionally substituted with Ci-C 6 straight or cyclicalkyl or Ci-C 6 straight or heterocyclicalkyl;
  • Z 4 is a COCH 3 group, a CO H 2 group, a CO H(CH 3 ) group
  • each n is independently 0, 1, 2 or 3..
  • alkoxy refers to an (alkyl)O— group.
  • alkyl group refers to an aliphatic hydrocarbon group.
  • alkyl group and hydrocarbon group are equivalent and may be used interchangeably.
  • the alkyl moiety may be a "saturated alkyl” group, which means that it does not contain any alkene or alkyne moieties.
  • the alkyl moiety may also be an "unsaturated alkyl” moiety, which means that it contains at least one alkene or alkyne moiety.
  • An “alkene” moiety refers to a group that has at least one carbon-carbon double bond
  • an “alkyne” moiety refers to a group that has at least one carbon-carbon triple bond.
  • alkyl moiety whether saturated or unsaturated, may be branched, straight chain or cyclic or heterocyclic.
  • an alkyl group can be a monoradical or a diradical (i.e. an alkylene group).
  • Ci-C x includes Ci-C 2 , C 1 -C3,— Ci-C x , wherein x is 2 to 10.
  • the "alkyl” moiety may have 1 to 10 carbon atoms (whenever it appears herein, a numerical range such as “1 to 10" refers to each integer in the given range; e.g. "1 to 10 carbon atoms” means that the alkyl group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term "alkyl” where no numerical range is designated).
  • the alkyl group of the compounds described herein may be designated as "Ci-C 6 alky” or similar designations.
  • Ci-C 6 alkyl indicates that there are 1 to 4 carbon atoms in the alkyl chain, e.g. the alkyl chain is selected from among methyl, ethyl, propyl, isopropyl, n-butly, isobutyl, sec-butyl and t-butyl.
  • Ci-C 6 alkyl includes Ci- C 2 alkyl and Ci-C 3 alkyl. Alkyl groups can be substituted or unsubstituted.
  • Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, penthyl, hexyl, ethenyl, propenyl, butenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
  • the alkyl group is a Ci-C 8 alkyl group.
  • the alkyl group is a Ci-C 6 alkyl group.
  • the alkyl group is a C 1 -C4 alkyl group.
  • the alkyl group is a Ci-C 3 alkyl group.
  • the alkyl group is a Ci-C 2 alkyl group.
  • the alkyl group is a Ci alkyl group.
  • An "amide” is a chemical moiety with the formula -C(0) HR or -NHC(0)R, where R is selected from among alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon).
  • An amide moiety may form a linkage between an amino acid or a peptide molecule and a compound described herein, thereby forming a prodrug. Any amine or carboxyl side chain on the compounds described herein can be amidified.
  • the amide may be an optionally substituted with Ci-C 6 straight or cyclicalkyl or a Ci-C 6 straight heterocyclicalkyl.
  • aryl refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom.
  • Aryl groups can be optionally substituted. Examples of aryl groups include, but are not limited to phenyl, naphthalenyl, phenanthrenyl, anthracencyl, fluorenyl and indenyl. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e. an arylene group).
  • aromatic refers to a planar ring having a delocalized ⁇ -electron system containing 4n+2 ⁇ electrons, where n is an integer. Aromatic rings can be formed by five, six, seven, eight, nine or more than nine atoms. Aromatics can be optionally substituted.
  • aromatic includes both carbocyclic aryl (e.g. phenyl) and heterocyclic aryl (or “heteroaryl” or “heteroaromatic”) groups (e.g. pyridine), the term includes monocyclic or fused-ring polycyclic (i.e. rings which share adjacent pairs of carbon atoms) groups.
  • heteroalkyl As used herein, the terms “heteroalkyl”, “heterocyclicalkyl”, “heteroalkenyl” and “heteroalkynyl” include optionally substituted alkyl, alkenyl and alkynyl radicals in which one or more skeletal chain atoms are selected from an atom other than carbon, e.g. oxygen, nitrogen, sulphur, silicon, phosphorus or combinations thereof.
  • the term "optionally substituted” or “substituted” means that the referenced group may be substituted with one or more additional group(s) individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, ahlo, carbonyl, thiocarbonyl, isocyanato, thiocyanate, isothiocyanato, nitro, perhaloalky, perfluoroalky, sily and amino, including mono- and di -substituted amino groups, and the protected derivatives thereof.
  • the protecting groups that may form the protective derivatives of the above substituents are known to
  • the compounds presented herein may possess one or more stereocenters and each center may exist in the R or S configuration.
  • the compounds presented herein include all diastereomeric, enantiomeric and epimeric forms as well as the appropriate mixtures thereof.
  • Stereoisomers may be obtained, if desired, by methods known in the art as, for example, the separation of stereoisomers by chiral chromatographic columns.
  • the methods and formulations described herein include the use of N-oxides, crystalline forms (also known as polymorphs), or pharmaceutically acceptable salts of compounds described herein, as well as active metabolites of these compounds having the same type of activity.
  • a "tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
  • Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors including temperature, solvent and pH.
  • an agent which inhibits TGF or TGF -R signaling includes but is not limited to an agent selected from the list consisting of 3-(6-methylpyridin-2-yl)- N-phenyl-4-quinolin-4-ylpyrazole-l-carbothioamide (also referred to as A83-01), 4-[4-2,3- dihyrdo-l,4-benzodioxin-6-yl)-5-(2-pyridynl)-lH-imidazol-2-yl]-benzamide, 4-[4-[3-(2- pyridynl)-lH-pyrazol-4-yl]-2-pyridynl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide, 4-[3-(2- pyridynl)-lH-pyrazol-4-yl]-quinoline, 2-(3-(6-methylpyridine-2-yl)-lH-pyrazole-l-carboth
  • a method for expanding a sample comprising mammalian mesenchymal stem cells (MSCs) into a population of substantially non-differentiated, multipotent MSCs in an in vitro culture comprising culturing the sample of cells in the presence of an agent selected from the list consisting of 3-(6-methylpyridin-2- yl)-N-phenyl-4-quinolin-4-ylpyrazole-l-carbothioamide, 4-[4-2,3-dihyrdo-l,4- benzodioxin-6-yl)-5-(2-pyridinyl)-lH-imidazol-2-yl]-benzamide, 4-[4-[3-(2-pyridinyl)- lH-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide, 4-[3-(2- pyridiny
  • MSCs mammalian mesenchymal stem cells
  • the method comprising subjecting a sample of cells comprising MSCs to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent selected from the list consisting of 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4- ylpyrazole-l-carbothioamide, 4-[4-2,3-dihyrdo-l,4-benzodioxin-6-yl)-5-(2-pyridinyl)-lH- imidazol-2-yl]-benzamide, 4-[4-[3-(2-pyridinyl)-lH-pyrazol-4-yl]-2-pyridinyl]-
  • the agent is 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4- ylpyrazole-l-carbothioamide or a pharmaceutically acceptable salt, solvate, tautomer or enantiomer thereof or a chemical derivative thereof.
  • This compound is referred to herein as "A83-01 ".
  • Variants and analogs and functional derivatives of A83-01 are also encompassed herein.
  • the amount of TGF /TGF R antagonist such as A83-01 includes but is not limited to from 0.1 ⁇ to 50 ⁇ such as 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 10, 20, 30, 40 and 50 ⁇ M.
  • MSCs mammalian mesenchymal stem cells
  • the MSCs include in an embodiment W5C5 + MSCs.
  • MSCs mammalian mesenchymal stem cells
  • the MSCs include in an embodiment W5C5 + MSCs.
  • the MSCs include eMSCs or pMSCs.
  • MSCs, eMSCs and pMSCs include MPCs, eMPCs and pMPCs, respectively.
  • the culture protocol taught by the present disclosure enables the generation of a population of MSCs including eMSCs and pMSCs which has a variety of clinical, diagnostic and drug discovery applications.
  • these include tissue regeneration, organ growth, repair and augmentation, tissue rejuvenation, cosmetic treatment or treatment of an inflammatory disease such as host versus graft disease, graft versus host disease or disease of the liver or lung or pelvic organ prolapse.
  • Other conditions include the treatment of circulatory disorders, bone disorders, cardiac disease, damaged or abnormal cartilage and hernia repair.
  • a method for cell therapy in a subject comprising administering to the subject, an effective amount of a population of non- differentiated MSCs generated by isolating a sample comprising MSCs from the same (autologous/homologous) subject or a different (allogeneic/heterologous) subject, culturing the cells in the presence of an agent which antagonizes a TGF -mediated signaling for a time and under conditions sufficient to expand the sample comprising MSCs into a population of multipotent cells, the administration being for a time and under conditions sufficient for the MSCs to differentiate into the selected tissue.
  • Taught herein is a method for cell therapy in a subject, the method comprising administering to the subject, an effective amount of a population of non-differentiated MSCs generated by isolating a sample comprising MSCs from the same (autologous/homologous) subject or a different (allogeneic/heterologous) subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent which antagonizes TGF -mediated signaling for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells, the administration being for a time and under conditions sufficient for the MSCs to differentiate into the selected tissue.
  • Taught herein is a method for cell therapy in a subject, the method comprising administering to the subject, an effective amount of a population of non-differentiated MSCs generated by isolating a sample comprising MSCs from the same (autologous/homologous) subject or a different (allogeneic/heterologous) subject, culturing the cells in the presence of an agent which antagonizes TGF -R-mediated signaling for a time and under conditions sufficient to expand the sample MSCs into a population of multipotent cells, the administration being for a time and under conditions sufficient for the MSCs to differentiate into the selected tissue.
  • a method for cell therapy in a subject comprising administering to the subject, an effective amount of a population of non- differentiated MSCs generated by isolating a sample comprising MSCs from the same (autologous/homologous) subject or a different (allogeneic/heterologous) subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent which antagonizes TGF -R-mediated signaling for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells, the administration being for a time and under conditions sufficient for the MSCs to differentiate into the selected tissue.
  • a method for cell therapy in a subject comprising administering to the subject, an effective amount of a population of non-differentiated MSCs generated by isolating a sample comprising MSCs from the same (autologous/homologous) subject or a different (allogeneic/heterologous) subject, culturing the cells in the presence of 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l- carbothioamide or a pharmaceutically acceptable salt, solvate, tautomer or enantiomer thereof or a chemical derivative thereof, the administration being for a time and under conditions sufficient for the MSCs to differentiate into the selected tissue.
  • the MSCs are W5C5 + MSCs.
  • a method for cell therapy in a subject comprising administering to the subject, an effective amount of a population of non-differentiated MSCs generated by isolating a sample comprising MSCs from the same (autologous/homologous) subject or a different (allogeneic/heterologous) subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of 3-(6- methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l-carbothioamide or a pharmaceutically acceptable salt, solvate, tautomer or enantiomer thereof or a chemical derivative thereof, the administration being for a time and under conditions sufficient for the MSCs to differentiate into the selected tissue.
  • the MSCs are W5C5 + MSCs.
  • TGF /TGF -R antagonists include but are not limited to 4-[4-2,3-dihyrdo-
  • the MSCs are eMSCs or pMSCs. In an embodiment, they are W5C5 + MSCs.
  • the agent is an antibody to TGF -R or a recombinant fusion protein targeting the receptor.
  • Reference to an "antibody” includes conventional monoclonal and polyclonal antibodies, derivatives and chimeric forms of antibodies such as humanized and deimmunized antibodies as well as cartilaginous marine animal-derived immunoglobulins (IgNARs) as well as camelid immunoglobulins.
  • the agent is a peptide or mimetic of the soluble TGF -R or a peptide or mimetic of a non- signaling form of TGF .
  • the agent is a genetic molecule which reduces expression of a particular gene encoding a component of the TGF signaling pathway.
  • Genetic agents include RNA, DNA, siRNA, microRNA, siDNA and the like.
  • the agent is a peptide aptamer or nucleic acid aptamer which inhibits a component in the TGF signaling pathway or a gene encoding same such as but not limited to TGF -R.
  • tissue therapy examples include tissue regeneration, organ growth, repair or augmentation, tissue rejuvenation, cosmetic treatment or treatment of an inflammatory or autoimmune disease include host versus graft and graft versus host disease, as well as cardiovascular disease, lung disease, liver disease, circulatory disorders, bone disease, pelvic organ prolapse, cartilage repair and hernia repair.
  • the present disclosure enables the production of a population of MSCs in non- differentiated, multipotent form.
  • the MSCs are eMSCs or pMSCs.
  • the protocol is a quality management system to reduce variability between batches of MSCs and between patients. It enables a more consistent outcome.
  • Taught herein is an isolated population of non-differentiated, multipotent MSCs generated by the method of isolating a sample comprising MSCs from a subject, culturing the cells in the presence of an agent which antagonizes a TGF -mediated signaling for a time and under conditions sufficient to expand the sample comprising MSCs into a population of multipotent cells.
  • Enabled herein is an isolated population of non-differentiated, multipotent MSCs generated by the method of isolating a sample comprising MSCs from a subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent which antagonizes TGF -mediated signaling for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells.
  • Also taught herein is an isolated population of non-differentiated, multipotent MSCs generated by the method of isolating a sample comprising MSCs from a subject, culturing the cells in the presence of an agent which antagonizes TGF -R-mediated signaling for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells.
  • the present specification is instructional on an isolated population of non- differentiated, multipotent MSCs generated by the method of isolating a sample comprising MSCs from a subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent which antagonizes TGF -R-mediated signaling for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells.
  • the specification enables a quality management system to reduce individual MSC variation. This in turn reduces the variability between patients treated and permits a more personalized medical approach to therapy.
  • Taught herein is an isolated population of non-differentiated, multipotent MSCs generated by the method of isolating a sample comprising MSCs from a subject, culturing the cells in the presence of an agent selected from the list consisting of 3-(6-methylpyridin- 2-yl)-N-phenyl-4-quinolin-4-ylpyrazole- 1 -carbothioamide, 4-[4-2,3 -dihyrdo- 1 ,4- benzodioxin-6-yl)-5-(2-pyridinyl)-lH-imidazol-2-yl]-benzamide, 4-[4-[3-(2-pyridinyl)- lH-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide, 4-[3-(2- pyridinyl)-lH-pyrazol-4-yl]-quinoline, 2-
  • Enabled herein is an isolated population of non-differentiated, multipotent MSCs generated by the method of isolating a sample comprising MSCs from a subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent selected from the list consisting of 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l- carbothioamide, 4-[4-2,3-dihyrdo-l,4-benzodioxin-6-yl)-5-(2-pyridinyl)-lH-imidazol-2- yl]-benzamide, 4-[4-[3-(2-pyridinyl)-lH-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H- pyran-4-yl)-benzamide,
  • Taught herein is an isolated population of non-differentiated, multipotent MSCs generated by the method of isolating a sample comprising MSCs from a subject, culturing the cells in the presence of 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l- carbothioamide or a pharmaceutically acceptable salt, solvate, tautomer, or enantiomer thereof or a chemical derivative thereof, for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells.
  • the MSCs can be produced on either a small scale or on a larger scale. In terms of small scale production, this may be effected in tissue culture flasks for example and may be suitable for producing populations of cells for a given individual and in the context of a specific condition.
  • One means of achieving large scale production in accordance with the method of the instant invention is via the use of a bioreactor, generally under hypoxic conditions.
  • the MSCs include eMSCs and pMSCs. In an embodiment, the MSCs are W5C5 + MSCs.
  • the present disclosure further teaches an isolated population of non-differentiated, multipotent MSCs generated by the method of isolating a sample comprising MSCs from a subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l-carbothioamide or a pharmaceutically acceptable salt, solvate, tautomer or enantiomer thereof or a chemical derivative thereof, for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells.
  • Bioreactors are designed to provide a culture process that can deliver medium and nitrogen at controlled concentrations and rates that mimic nutrient concentrations and rates in vivo. Bioreactors are available commercially and employ a variety of types of culture technologies. Of the different bioreactors used for mammalian cell culture, most have been designed to allow for the production of high density cultures of a single cell type and as such find use in the present invention. In most instances, expansion and use of cultured MSCs require the use of suitable microcarriers or beads for adhesion and proliferation of the undifferentiated MSCs. Those skilled in the art will be aware of the range of possible synthetic and biological carriers including surface coated carriers to allow efficient MSC adhesion.
  • Also included in the present invention is a means of culturing and expanding undifferentiated MSCs on biomaterial scaffolds and meshes of both synthetic and natural origin intended for clinical intervention for tissue repair and regeneration including, for example, but not restricted to, the repair of damaged pelvic organ prolapse, cartilage repair and hernia repair.
  • the development of the cell culture protocol facilitates the development of means for therapeutically or prophylactically treating subjects based on administering to those patients a population of expanded MSCs.
  • the protocol enables a quality management system to reduce individual MSC variation. This in turn reduces the variability between patients treated and permits a more personalized medical approach to therapy.
  • Reference to "administering" to a subject means providing an effective number of MSCs to the mammal, such as a human.
  • the subject cells are generally autologous (homologous) or allogeneic (heterologous) MSCs expanded in culture to allow sufficient amplification of a source of therapeutic undifferentiated MSCs. It should be understood, however, that the purpose of these expanded MSCs for cell therapies or tissue engineering could include paracrine effects from those subject cells or differentiation of these cells in vivo to replace diseased or damaged cells and tissue.
  • Reference to an "effective amount” means that number of cells necessary to at least partly attain the desired effect, or to delay the onset of, inhibit the progression of, or halt altogether the onset or progression of the particular condition being treated. Such amounts will depend, of course, on the particular conditions being treated, the severity of the condition and individual patient parameters including age, physical conditions, size, weight, physiological status, concurrent treatment, medical history and parameters related to the disorder in issue. One skilled in the art would be able to determine the number of cells and tissues of the present invention that would constitute an effective dose, and the optimal mode of administration thereof without undue experimentation. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. Generally, a maximal cell number is used which is the highest safe number according to sound medical judgement. It will be understood by those of ordinary skill in the art, however, that a lower cell number may be administered for medical reasons, psychological reasons or for any other reasons.
  • the cells which are administered to the patient can be administered as single or multiple doses by any suitable route. Where possible, a single administration is utilized. Administration via injection can be directed to various regions of a tissue or organ, depending on the type of repair required. The cells which are administered to the patient can be administered as single or multiple doses by any suitable route. Where possible, a single administration is utilized. Administration via injection can be directed to various regions of a tissue or organ, depending on the type of repair required. It would also be appreciated by those skilled in the art, that a variety of cell delivery systems could be used with the subject cells, including those derived from synthetic or biological materials including but not restricted to hydrogels, meshes, patches, sponges. Use of these systems could assist in retention of the delivered subject cells to the site of administration.
  • these systems can be used as part of the tissue engineered product along with embedded or seeded subject cells that allow either retention of the subject cells in the undifferentiated state or controlled differentiation of subject cells towards cells and tissues required for replacement of the damaged tissue.
  • Detailed guidelines for generating or obtaining suitable scaffolds, culturing such scaffolds and therapeutically implanting such scaffolds are available in the literature (for example, refer to Kim and Vacanti (1999) Semin Pediatr Surg. 8: 119, U.S. Patent No. 6,387,369 and U.S. Patent Application No. US20020094573 Al).
  • the subject undergoing treatment or prophylaxis may be any human or animal in need of therapeutic or prophylactic treatment.
  • treatment and prophylaxis are to be considered in its broadest context.
  • the term “treatment” does not necessarily imply that a mammal is treated leading to total recovery.
  • prophylaxis does not necessarily mean that the subject will not eventually contract a disease condition.
  • treatment and prophylaxis include amelioration of the symptoms of a particular condition or preventing or otherwise reducing the risk of developing a particular condition.
  • the term “prophylaxis” may be considered as reducing the severity of the onset of a particular condition. “Treatment” may also reduce the severity of an existing condition.
  • the subject being treated is a human.
  • the present disclosure extends to veterinary applications.
  • Another aspect of the present invention is directed to the use of a population of MSCs generated by the method of isolating a sample comprising MSCs from a subject, culturing the cells in the presence of an agent which antagonizes TGF -mediated signaling for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells in the manufacture of a medicament for cell therapy in a subject.
  • a population of MSCs generated by the method of isolating a sample comprising MSCs from a subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent which antagonizes TGF -mediated signaling for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells in the manufacture of a medicament for cell therapy in a subject.
  • the present specification is instructional on the use of a population of MSCs generated by the method of isolating a sample comprising MSCs from a subject, culturing the cells in the presence of an agent which antagonizes TGF -R-mediated signaling for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells in the manufacture of a medicament for cell therapy in a subject.
  • Taught herein is the use of a population of MSCs generated by the method of isolating a sample comprising MSCs from a subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent which antagonizes TGF -R- mediated signaling for a time and under conditions sufficient to expand the sample of enriched MSCs into a population of multipotent cells in the manufacture of a medicament for cell therapy in a subject.
  • Another aspect of the present invention is directed to the use of a population of MSCs generated by the method of isolating a sample comprising MSCs from a subject and culturing the cells in the presence of an agent selected from the list consisting of 3-(6- methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l-carbothioamide, 4-[4-2,3- dihyrdo-l,4-benzodioxin-6-yl)-5-(2-pyridinyl)-lH-imidazol-2-yl]-benzamide, 4-[4-[3-(2- pyridinyl)-lH-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide, 4-[3- (2-pyridinyl)-lH-pyrazol-4-yl]-quinoline, 2-(3-(6-
  • a population of MSCs generated by the method of isolating a sample comprising MSCs from a subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of an agent selected from the list consisting of 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l-carbothioamide, 4-[4-2,3- dihyrdo-l,4-benzodioxin-6-yl)-5-(2-pyridinyl)-lH-imidazol-2-yl]-benzamide, 4-[4-[3-(2- pyridinyl)-lH-pyrazol-4-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-benzamide, 4-[3- (2-pyridin
  • Another aspect of the present invention is directed to the use of a population of MSCs generated by the method of isolating a sample comprising MSCs from a subject, culturing the cells in the presence of 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4- ylpyrazole-l-carbothioamide or a pharmaceutically acceptable salt, solvate, tautomer or enantiomer thereof or a chemical derivative thereof in the manufacture of a medicament for cell therapy in a subject.
  • a population of MSCs generated by the method of isolating a sample comprising MSCs from a subject, exposing the sample of cells to enrichment of MSCs by selection of a cell surface marker expressed by the MSCs followed by culturing the enriched cells in the presence of 3-(6-methylpyridin-2-yl)-N-phenyl-4- quinolin-4-ylpyrazole-l-carbothioamide or a pharmaceutically acceptable salt, solvate, tautomer or enantiomer thereof or a chemical derivative thereof in the manufacture of a medicament for cell therapy in a subject.
  • a diagnostic method of assessing the effect of new drugs or small molecules in a treatment protocol or culture regime comprising subjecting a population of non- differentiated, multipotent MSCs produced by the method herein to the treatment or culture regime and screening for retention of the original uncultured phenotype.
  • the present specification is instructional on a means of optimizing a treatment which is designed to normalize and maintain MSC-derived cellular functioning.
  • the method can also be used to assess the toxicity of a treatment, in particular a treatment with a compound.
  • failure to generate a characteristic associated with a mesenchymal or mesenchymal -derived phenotype in the cells and tissues of the present invention in response to treatment with a compound can be used to assess the toxicity of such a compound.
  • the treatment to which the cells or tissues of the present invention are subjected is an exposure to a drug.
  • the drug is a chemical compound, peptide or protein, or a nucleic acid molecule.
  • the compound can be a growth factor or differentiation factor.
  • Kits are also contemplated herein for use in expanding population of MSCs for use in therapy, diagnosis and drug discovery and evaluation.
  • the kit may be in the form of a therapeutic kit or a pre-medicament kit.
  • the kit is in compartment form wherein one compartment comprises a matrix support for cells.
  • An example is gelatine/polyamide mesh. Expanded MSCs are seeded onto the mesh.
  • the kit may further comprise culture fluid such as one or more of the media listed in Table 2.
  • the medium is the serum free medium.
  • the media or medium may be in liquid form or is capable of being reconstituted in liquid form.
  • the kit may also contain fibronectin for coating the mesh prior to cell seeding. Additional components include but are not limited to a TGF -signaling inhibitor (e.g. A83-01) and a growth factor.
  • the kit may further be designed to act as a receptacle for components and/or reagents alone or as a culture vessel for culturing the MSC-seeded mesh.
  • the kit is designed for MSC enrichment and culturing.
  • eMSC were isolated from endometrial tissues obtained from hysterectomy tissue which were carefully scraped off the underlying myometrium. Both hysterectomy and curette tissues were mechanically minced and digested with 0.5% w/v collagenase type I and 40 ⁇ g/ml deoxyribonuclease type I (both Worthington Biochemical Corporation) in Dulbecco's modified Eagle's medium (DMEM/F12) for 90 and 60 minutes, respectively in a humidified incubator at 37°C on a rotating MACSmix (Miltenyi Biotech). The tissue digest was filtered through 40 ⁇ cell strainer (BD Biosciences) to separate the epithelial gland fragments and undigested tissues.
  • DMEM/F12 Dulbecco's modified Eagle's medium
  • the red blood cells in the filtrate were separated from the single stromal cells by density gradient centrifugation using Ficoll-Paque (GE healthcare Bio-science).
  • eMSC were obtained by incubating the stromal cells in Phycoerythrin (PE)-conjugated anti-human SUSD2 (10 ⁇ g/ml, BioLegend) in 0.5% v/v FCS/PBS (bead medium) and anti-PE magnetic-activated cell sorting microbeads (Miltenyi Biotec) for 30 minutes each in the dark on ice.
  • the conjugated pellet was resuspended in bead medium and applied to a Miltenyi column (Miltenyi Biotec, #130-042-201) in a magnetic field.
  • the separated cells, containing the SUSD2+ eMSCs in the column were eluted in bead medium and the cells counted.
  • the SUSD2+ eMSC were initially maintained in DMEM/F12 medium containing 10%) v/v fetal calf serum (FCS) (Invitrogen), 1%> w/v antibiotic-antimycotic (Life Technologies) and 2mM glutamine and slowly changed to a DMEM/F12 serum free medium supplemented with basic fibroblast growth factor (FGF2, lOng/ml) and epidermal growth factor (EGF, lOng/ml) (SFM) at 37°C in 5% v/v 0 2 /5% v/v CO 2 /90% v/v N, as described previously22.
  • FCS v/v fetal calf serum
  • FGF2 basic fibroblast growth factor
  • EGF epidermal growth factor
  • SFM epidermal growth factor
  • the cells were seeded at 5000 cells/cm 2 density at subsequent passages in fibronectin (10 ⁇ / ⁇ 1) pre-coated culture flasks.
  • Cell proliferation assays were performed at passage 3 by seeding 1000 cells in ⁇ SFM per well in fibronectin pre- coated 96-well plates with or without A83-01, concentrations varying from 0- ⁇ . Medium was changed every second day and contained A83-01 at the same concentration.
  • 20 ⁇ 1 of MTS tetrazolium reagent Promega
  • Further experiments were done at passage 6 where the cells were separated into two groups, one group was treated with 1 ⁇ A83-01 and the control with (0.01% v/v DMSO) vehicle. The data were normalized to the control and reported as a percentage.
  • eMSC were trypsinized with TrypLETM (Life technologies, #12604-021)) and resuspended at 10 5 cells/tube.
  • Cells were washed with 5% v/v heat-inactived newborn calf serum in DMEM (bench medium) and incubated with PE-, APC- or FITC-conjugated primary antibodies or matched-isotype controls in bench medium for 30 minutes in the dark on ice.
  • Primary antibody used was CD146 (1 : 1 supernatant, clone CC9, (CSIRO, Australia).
  • PE-conjugated antibodies were SUSD2 (1 :20, Biolegend, #327406), CD140b (1 :20, R&D systems FAB1263P) and CD271 (1 :20, Miltenyi Biotec).
  • APC-conjugated antibody was CD90 (1 :20, BD Pharmingen).
  • Isotype control antibodies at the same concentration as the primary antibody were included for each run and were used to set the electronic negative control gate on the flow cytometer.
  • cells were washed with bench medium and fixed with 4% v/v paraformaldehyde (PFA) in 2% v/v FBS/PBS. Samples were analyzed using a MoFlo Flow Cytometry (Beckman Coulter) and Summit software (version 5.2., Beckman Coulter).
  • Passage 6 (P6) eMSC were cultured on coverslips with or without ⁇ ⁇ A83-01 for 7 days and then fixed in 4% v/v PFA followed by protein block (Dako, X0909) for 10 minutes each at room temperature with washing in between with PBS.
  • PE-conjugated SUSD2 antibody (1 :200, BioLegend, #327406) in 2% v/v FCS/PBS was incubated for 2 hours at room temperature in dark.
  • Isotype control IgGl antibody was used as a negative control.
  • Hoechst 33258 (1 :2000, Molecular Probes) was used to visualize nuclei. Images were visualized and photographed using a Delta Vision microscope, and analyzed using ImageJ software (ImageJ-win32.Ink). Immunoblotting
  • Cell lysates were prepared using lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% v/v triton X-100) with mini protease inhibitor cocktail tablet (Roche) and phosphatase inhibitor sodium vanadate (2 mM).
  • the following antibodies were used: anti-SMAD 2/3 antibody (#3102S), antiphospho-SMAD 2/3 (#8828S), horseradish peroxidise conjugated secondary antibody (#7074S) from Cell Signaling Technology.
  • the specific protein was detected by treating the membrane for two minutes with enhanced chemiluminescence (# 133406, Abeam) which provides the HRP substrate, and capturing the signal in X-ray films.
  • the PCR conditions consisted of initial denaturation at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 seconds and annealing/polymerization at 60°C for 60 seconds.
  • Primer sets are detailed in Table 1 (F, Forward primer; R, Reverse primer). GAPDH or ⁇ -Actin was used as an endogenous control to normalize the target gene expression and fold change was calculated using the 2 " CT method.
  • P6eMSC pre-treated and untreated with ⁇ ⁇ A83-01 for 7 days were seeded at 50 and 100 cells/cm 2 on fibronectin-coated 100mm culture dishes (BD Falcon) in SFM in a tri-gas incubator 5% v/v 0 2 /5% v/v CO 2 /90% v/v N for four weeks.
  • the cells were then formalin-fixed for 10 minutes and stained with haematoxylin (AMBER SCIENTIFIC).
  • the colonies were washed twice with distilled water and counterstained with Scott's tap water to develop the blue color. Colony efficiency was calculated by counting the number of colonies divided by the number of cells seeded and the percentage determined.
  • the remaining cells were cultured in adiopogenic and osteogenic, and control medium (1% v/v fetal calf serum) on 13-mm coverslips, and for chondrogenic differentiation the cells were cultured as 3D pellets in chondrogenic induction media for 4 weeks at 37°C in 5% v/v C0 2 /5% v/v 0 2 as previously described (Rajaraman et al. (2013) supra).
  • the cells were fixed with 4% w/v PFA and incubated with 1% v/v Oil Red O for adipogenesis, 4% w/v Alizarin Red (pH 4.1) for osteogenesis and 1% w/v Alcian blue (pH 2.5) on paraffin embedded sections (5 ⁇ ) of the micromass pellet for chondrogenesis. Stained cells were examined under an Olympus BX41 microscope (Olympus) and images were taken with 10X objective lens using the DP25 digital camera (Olympus).
  • P6 A83-01 treated and untreated cells were detached, pelleted and fixed in ice-cold 70% v/v ethanol at 4°C overnight. They were washed with 2%FBS/PBS and incubated with 50 ⁇ 1 RNAse (10( g/ml, Sigma) at room temperature for 15 minutes. 200 ⁇ 1 of propidium iodide (PI) (50 ⁇ g/ml, Sigma P4170) was added and the cells were analyzed immediately by flow cytometry using BD FACS Canto (Trade Mark) II on Pi-linear scales. The data were analyzed using FlowJo 7.6.3.
  • PI propidium iodide
  • Senescent cells were assessed by staining for beta-galactosidase activity.
  • P6 A83- 01 treated and untreated eMSC were cultured on coverslips for 7 days as described above, then fixed in 4% v/v PFA for 10 minutes and stained in freshly prepared X-Gal (lmg/ml in DMSO) staining reagent (5mM K 3 Fe(CN), 5mM K 4 Fe(CN), 2mM MgCl 2 , 150mM NaCl) in citrate buffer at pH6 for 24 hours at 37°C.
  • the cells were washed twice with PBS and counter stained with nuclear fast red (Sigma-Aldrich, 0.1% w/v) for 10 minutes, then examined under an Olympus BX41 microscope (Olympus). Images were taken with 10X objective lens using the DP25 digital camera (Olympus).
  • Non parametric Friedman's test with Dunn's multiple comparison post hoc tests were used to test for multiple groups and Wilcoxon matched-pairs signed rank tests were used to test for statistical significance between treated and control groups. Data are presented as mean ⁇ standard error of mean. Differences were considered statistically significant at p ⁇ 0.05.
  • NANOG F TAATAACCTTGGCTGCCGTCTCTG 3
  • SUSD2 F AGAGCTGGATGGACCTGAAA 7
  • CD146 F GAAGCATGGGGCTTCCCAG 9
  • AOC3 F TCAGCTGGGAGAGGATTTGG 11
  • NOTCH3 F GGACCTGCCGTGGCT ATA 23
  • GAPDH F TGTGGGCATCAATGGATTTGG 25
  • red blood cells are removed by density gradient centrifugation by underlying 3ml Ficoll- Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) at 1500 rpm for 15 minutes at room temperature. Cells are collected from the medium/Ficoll interface and counted using trypan blue. The stromal cell pellet is incubated in ⁇ of buffer with 5 ⁇ 1 W5C5-PE antibody (Miltenyi Biotec) [ ⁇ g/ml] for 10-30 minutes at 4°C in dark.
  • 5 ⁇ 1 W5C5-PE antibody Miltenyi Biotec
  • the cell suspension is passed through the MACS column (Miltenyi Biotec) in the magnetic field. The column is washed with 500 ⁇ 1 buffer three times. The column is removed from the magnetic field and placed in a sterile tube. An aliquot of 1ml of buffer is applied to the cells to flush out W5C5 + eMSCs and the cells counted.
  • AlbuMaxI is a lipid-rich bovine serum albumin. It is chromatographically purified and has an IgG content of ⁇ 0.1% w/v. ITS-A is insulin-transferrin-selenium-sodium pyruvate. EXAMPLE 2
  • A83-01 (3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-l- carbothioamide) enables culture expansion of eMSCs in their undifferentiated state in serum free medium (Table 2) under hypoxic conditions.
  • A83-01 is used at a concentration of ⁇ .
  • Targeting the TGF -R signaling pathway increased human eMSC clonogenicity during culture expansion (Figure 3), generating an increased proportion of W5C5 + eMSCs ( Figure 1), an effect regulated by Smad 2/3 signaling.
  • the effect of A83-01 was greater on MSC derived from older compared to younger women.
  • the culture protocol using A83-01 may have greater application when using autologous MSC as they frequently can be derived from older women.
  • eMSCs can be isolated from postmenopausal women given short term estrogen treatment (Tables 3 and 4) [Ulrich et al. (2014) Human Reproduction 29;1895-1905]. This group of patients are generally in an age group that might be seeking a cell based therapy using their own cells.
  • oestradiol valerate product name Progynova
  • Progynova a precursor of oestradiol for a few weeks to increase the thickness of endometrium in order to provide sufficient tissue to harvest.
  • the cells were then cultured in the presence or absence of ⁇ ⁇ A83-01 as described in the Materials and Methods and in Examples 1 and 2. Following culture, markers CD146, CD90, W5C5 and CD140b were used for flow cytometric analysis.
  • Table 4 provides actual values in A83-01 untreated versus A83-01 treated cells. The values are the percentage of positive cells expressing individual markers. These data are also represented graphically in Figure 4. Table 4
  • SUSD2+ cells diminished in number with increasing passage (Ulrich et al. (2014) Cell Transplant 27:2201-2214), despite their high purity on initial seeding following SUSD2 magnetic bead sorting (Masuda et al. (2012) Cell Transplant 27:2201-2214).
  • A83-01 on eMSC proliferation passage 3 eMSC were cultured in SFM in 5% v/v 0 2 with A83-01 concentrations ranging from 0- 10 ⁇ for 7 days. Control medium was supplemented with vehicle. The MTS cell viability end-point assay was used to assess the effect of A83-01 on eMSC growth.
  • A83-01 maintained functional properties of late passage eMSC
  • A83-01 pre- treated and untreated cells showed similar phenotype changes in adiopogenic medium with similar numbers of cells containing Oil Red O stained lipid droplets. Similarly for osteogenic differentiation, the amount of Alizarin Red stained calcium deposits was comparable. In contrast, chondrogenic differentiation of the cell pellets was greater for the A83-01 pre-treated cells, as a strong Alcian Blue stained matrix in a cartilage-like organoid was observed, while the untreated eMSC pellet disintegrated easily with little evidence of chondroitin sulphate matrix deposition (Figure 7C). There was no differentiation in non- induction medium.
  • A83-01 blocks apoptosis and senescence in P6 eMSC
  • FIG. 9A To identify the mechanism of action of A83-01 in increasing eMSC proliferation (Figure 5), cell cycle analysis ( Figure 9A) was undertaken with propidium iodide to label DNA.
  • Figure 9A and B shows that A83-01 treatment increased the proportion of cells in G2/M phase (p ⁇ 0.05) indicative of an increased rate of cell division.
  • the apoptotic cells were quantitated using Annexin V flow cytometry to assess early phase apoptosis. The inclusion of PI was to detect late apoptotic and necrotic cells.
  • SAP-Gal senile associated ⁇ -Gal
  • FIG. 9F A83-01 treated P6 eMSC showed little ⁇ -Gal staining whereas the untreated control eMSC displayed blue staining indicative of senescent cells. Furthermore the A83 -01 -treated cells were smaller and more numerous, in agreement with the findings above.
  • A83-01 a small molecule TGF-PR inhibitor, prevented the typical loss of undifferentiated MSC during culture expansion. Specifically, we showed that A83-01 treatment prevented loss of SUSD2+ eMSC in late passage cultures by promoting the mitosis and proliferation of P6 SUSD2+eMSC and by preventing their apoptosis and senescence. A83-01 treated SUSD2+ cells in late passage culture retained their MSC properties, showing greater clonogenicity then untreated cells. In particular, there were greater numbers of large colonies which undergo serial cloning and are more proliferative than those initiating small colonies (Gargett et al. (2009) supra).
  • TGF-PR signaling is necessary for chondrogenic differentiation (Ng et al. (2008) Blood 772:295-307).
  • the experimental medium for eMSC culture expansion contained A83-01
  • the chondrogenic differentiation medium contained TGF- ⁇ without A83-01 to assess chondrogenic differentiation potential of A83-01 treated and untreated cells.
  • One advantage of using small molecules rather than siRNA to modulate receptor activity is that their inhibitory effect is reversed as soon as the small molecules are removed. It is shown here that chondrogenic differentiation was enhanced in A83-01 pre-treated cells.
  • A83-01 not only increased the expression of SUSD2 proteins but also CD140b.
  • CD146 gene expression was greater in the untreated group but did not appear to be translated into protein as it was not detected by flow cytometry.
  • CD146 on cultured MSC is regulated by factors such as hypoxia, growth factors, and metalloproteases (Rawdanowicz et al. (1994) J. Clin. Ednocrinol. Metab. 79:530-536; Boneberg et al. (2009) Microvasc. Res. 75:325-331).
  • Culture expanded MSC are more autofluorescent than the primary cells indicating replicative senescence and loss of proliferative ability (Wagner et al. (2008) PloS one 3:e2213; Constantinescu et al. (2007) J. Neural transm. Suppl. : ⁇ 7-2&) an effect observed in P6 control eMSC which was mitigated by A83-01 treatment.
  • Endometrial MSC are an attractive source of cells for tissue engineering and cell- based therapies because they can be harvested with minimal discomfort to patients, have standard MSC properties in vitro and in vivo and they can be cultured in serum free conditions, offering a readily available cell source for allogeneic as well as autologous use.
  • TGF-PR signaling is involved in eMSC cell fate in vitro.
  • A83-01 a small molecule TGF-PR inhibitor, enhanced the expression of SUSD2 and CD 140b, maintaining eMSC clonogenic phenotype during prolonged culturing, promoting cell proliferation and preventing apoptosis and senescence.
  • Small molecules such as A83-01 that promote eMSC proliferation in the undifferentiated state provide an approach for the expansion of undifferentiated MSC for use in tissue engineering and cell-based therapies.
  • Placental cells were obtained and prepared as described in the Materials and Methods and Examples 1 and 2. The cells were immuno-selected with W5C5 antibody at passage 1 and cultured in serum free medium until passage 6 when they were grouped into untreated and treated with ⁇ ⁇ A83-01 and subjected to flow cytometry generating a percentage of cells expressing the individual markers CD146, CD90, W5C5 and CD140b (percent positive cells). The percentage range of W5C5 + cells was large in untreated compared to treated cells (Table 5; Figure 11). This indicates that A83-01 treatment served as a significant quality management system to control the expanded cell population.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne, d'une manière générale, un procédé de culture cellulaire pour les cellules souches mésenchymateuses et d'autres cellules de lignée apparentée. L'invention concerne également des populations de cellules destinées à être utilisées en tant que médicaments cellulaires et dans des thérapies à base de cellules et de génie tissulaire, dans des diagnostics et dans des protocoles de criblage pour agents thérapeutiques. Le procédé permet la production de cellules souches mésenchymateuses d'un niveau uniforme et constitue, par conséquent, un système de gestion de la qualité.
PCT/AU2015/050498 2014-08-27 2015-08-27 Procédé de culture de cellules souches mésenchymateuses Ceased WO2016029267A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014903390 2014-08-27
AU2014903390A AU2014903390A0 (en) 2014-08-27 A method for culturing mesenchymal stem cells

Publications (1)

Publication Number Publication Date
WO2016029267A1 true WO2016029267A1 (fr) 2016-03-03

Family

ID=55398504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2015/050498 Ceased WO2016029267A1 (fr) 2014-08-27 2015-08-27 Procédé de culture de cellules souches mésenchymateuses

Country Status (1)

Country Link
WO (1) WO2016029267A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017164467A1 (fr) * 2016-03-25 2017-09-28 (주)안트로젠 Culture de cellules souches mésenchymateuses pour la prévention ou le traitement d'une maladie immunitaire ou d'une maladie inflammatoire et procédé de préparation associé
EP3932388A1 (fr) * 2020-06-30 2022-01-05 Miraecellbio Co., Ltd. Procédé de préparation de cellules souches de type mésenchymateuses et cellules souches de type mésenchymateuses ainsi préparées
CN114480268A (zh) * 2022-01-21 2022-05-13 深圳市茵冠生物科技有限公司 人脐带间充质干细胞的制备方法
CN115094025A (zh) * 2022-07-14 2022-09-23 北京中科细胞控股有限公司 子宫内膜基质干细胞的制备方法
CN115651897A (zh) * 2022-10-18 2023-01-31 江苏省中医药研究院 一种子宫内膜间充质干细胞分离、纯化及扩增试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070128719A1 (en) * 2003-05-22 2007-06-07 Tissuetech, Inc. Isolation and expansion of animal cells in cell cultures
WO2007116870A1 (fr) * 2006-04-03 2007-10-18 Effector Cell Institute, Inc. Procédé de préparation de cellules analogues aux hépatocytes matures
US20080175816A1 (en) * 2007-01-22 2008-07-24 Board Of Trustees Of The University Of Arkansas Maintenance and Propagation of Mesenchymal Stem Cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070128719A1 (en) * 2003-05-22 2007-06-07 Tissuetech, Inc. Isolation and expansion of animal cells in cell cultures
WO2007116870A1 (fr) * 2006-04-03 2007-10-18 Effector Cell Institute, Inc. Procédé de préparation de cellules analogues aux hépatocytes matures
US20080175816A1 (en) * 2007-01-22 2008-07-24 Board Of Trustees Of The University Of Arkansas Maintenance and Propagation of Mesenchymal Stem Cells

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AI, W.J. ET AL.: "Regulation of ALK5 receptor signaling promotes differentiation of endothelial cells from mesenchymal stem cells and its application to tissue engineered blood vessel", JOURNAL OF SUN YAT-SEN UNIVERSITY. MEDICAL SCIENCES, vol. 34, 2013, pages 207 - 214 *
GARGETT, C.E. ET AL.: "Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium", BIOLOGY OF REPRODUCTION, vol. 80, 2009, pages 1136 - 1145 *
GURUNG, S. ET AL.: "Inhibition of Transforming Growth Factor-beta Receptor signaling promotes culture expansion of undifferentiated human Endometrial Mesenchymal Stem/stromal Cells", SCIENTIFIC REPORTS, vol. 5, October 2015 (2015-10-01) *
JEON, E.S. ET AL.: "Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-like cells through a TGF-beta-dependent mechanism", JOURNAL OF CELL SCIENCE, vol. 119, 2006, pages 4994 - 5005 *
NIGRO, J. ET AL.: "The effect of bovine endosteum-derived particles on the proliferation of human mesenchymal stem cells", BIOMATERIALS, vol. 31, 2010, pages 5689 - 5699, XP027059070 *
RAJARAMAN, G. ET AL.: "Optimization and scale-up culture of human endometrial multipotent mesenchymal stromal cells: potential for clinical application", TISSUE ENGINEERING PART C: METHODS, vol. 19, 2013, pages 80 - 92 *
ROELEN, B.A.J. ET AL.: "Controlling mesenchymal stem cell differentiation by TGEbeta family members", JOURNAL OF ORTHOPAEDIC SCIENCE, vol. 8, 2003, pages 740 - 748 *
WU, J. ET AL.: "`TGF-(31 induces senescence of bone marrow mesenchymal stem cells via increase of mitochondrial ROS production", BMC DEVELOPMENTAL BIOLOGY, vol. 14, May 2014 (2014-05-01), XP021185604, DOI: doi:10.1186/1471-213X-14-21 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017164467A1 (fr) * 2016-03-25 2017-09-28 (주)안트로젠 Culture de cellules souches mésenchymateuses pour la prévention ou le traitement d'une maladie immunitaire ou d'une maladie inflammatoire et procédé de préparation associé
EP3932388A1 (fr) * 2020-06-30 2022-01-05 Miraecellbio Co., Ltd. Procédé de préparation de cellules souches de type mésenchymateuses et cellules souches de type mésenchymateuses ainsi préparées
CN114480268A (zh) * 2022-01-21 2022-05-13 深圳市茵冠生物科技有限公司 人脐带间充质干细胞的制备方法
CN114480268B (zh) * 2022-01-21 2024-01-30 深圳市茵冠生物科技有限公司 人脐带间充质干细胞的制备方法
CN115094025A (zh) * 2022-07-14 2022-09-23 北京中科细胞控股有限公司 子宫内膜基质干细胞的制备方法
CN115094025B (zh) * 2022-07-14 2022-11-08 北京中科细胞控股有限公司 子宫内膜基质干细胞的制备方法
CN115651897A (zh) * 2022-10-18 2023-01-31 江苏省中医药研究院 一种子宫内膜间充质干细胞分离、纯化及扩增试剂盒及其应用

Similar Documents

Publication Publication Date Title
Gurung et al. Inhibition of transforming growth factor-β receptor signaling promotes culture expansion of undifferentiated human endometrial mesenchymal stem/stromal cells
Zhu et al. Lithium stimulates human bone marrow derived mesenchymal stem cell proliferation through GSK‐3β‐dependent β‐catenin/Wnt pathway activation
Ma et al. CD146 controls the quality of clinical grade mesenchymal stem cells from human dental pulp
Arufe et al. Differentiation of synovial CD‐105+ human mesenchymal stem cells into chondrocyte‐like cells through spheroid formation
EP3342858B1 (fr) Cellules souches mésenchymateuses positives à ror1 et leur procédé de préparation, composition pharmaceutique les contenant et son procédé de préparation, et méthode destinée à prévenir ou à traiter des maladies à l'aide desdites cellules souches mésenchymateuses positives à ror1
Raynaud et al. Comprehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation
JPWO2018164228A1 (ja) Ｒｏｒ１陽性の間葉系幹細胞を含有する、線維症を伴う疾患の予防又は処置のための医薬組成物、及びその調製方法、並びにｒｏｒ１陽性の間葉系幹細胞を用いる線維症を伴う疾患の予防又は処置方法
Tsai et al. Endothelial cells direct human mesenchymal stem cells for osteo-and chondro-lineage differentiation through endothelin-1 and AKT signaling
Zhang et al. Effects of platelet-rich plasma on the activity of human menstrual blood-derived stromal cells in vitro
Li et al. Rho kinase inhibitor Y-27632 promotes the differentiation of human bone marrow mesenchymal stem cells into keratinocyte-like cells in xeno-free conditioned medium
Grotheer et al. Osteogenic differentiation of human mesenchymal stromal cells and fibroblasts differs depending on tissue origin and replicative senescence
Albiero et al. Exposure of periodontal ligament progenitor cells to lipopolysaccharide from Escherichia coli changes osteoblast differentiation pattern
Gnanasegaran et al. Different isolation methods alter the gene expression profiling of adipose derived stem cells
KR102150244B1 (ko) ＰＩ３Ｋ／ＡＫＴ／ＧＳＫ３ 경로를 통해 성체줄기세포의 증식, 다분화능 및 재프로그래밍을 촉진하는 ＣＤ４９ｆ
Pei et al. Expansion on a matrix deposited by nonchondrogenic urine stem cells strengthens the chondrogenic capacity of repeated-passage bone marrow stromal cells
WO2016029267A1 (fr) Procédé de culture de cellules souches mésenchymateuses
Bok et al. The role of human umbilical vein endothelial cells in osteogenic differentiation of dental follicle-derived stem cells in in vitro co-cultures
CN114729329A (zh) Lbm、cpc、opc、它们的制备和质量控制方法、试剂盒、移植材料和疾病模型
JP7069492B2 (ja) 類似間葉系幹細胞の製造方法及びこれにより製造された類似間葉系幹細胞
Kurenkova et al. Notch signaling regulates the chondrogenic potential of both articular chondrocytes and their progenitors during expansion
WO2021125340A1 (fr) Milieu de culture et de multiplication de cellules progénitrices de néphron, procédé de culture et de multiplication de cellules de cellules progénitrices de néphron, et procédé de production d'organoïdes rénaux
Shi et al. The effect of extended passaging on the phenotype and osteogenic potential of human umbilical cord mesenchymal stem cells
Di Felice et al. OPLA scaffold, collagen I, and horse serum induce a higher degree of myogenic differentiation of adult rat cardiac stem cells
WO2023032945A1 (fr) Agent thérapeutique pour l'arthropathie, et procédé de production d'agent thérapeutique pour l'arthropathie
Wang et al. Extracellular matrix deposited by Wharton’s jelly mesenchymal stem cells enhances cell expansion and tissue specific lineage potential

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15835792

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15835792

Country of ref document: EP

Kind code of ref document: A1